VHAM
ITCI

Van Hulzen Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Van Hulzen Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,600
Closed -$607K – 342
2025
Q1 		$607K Sell
4,600
-400
-8% -$49.8K 0.06% 192
2024
Q4 		$418K Hold
5,000
– – 0.03% 236
2024
Q3 		$366K Sell
5,000
-300
-6% -$22.5K 0.03% 243
2024
Q2 		$363K Hold
5,300
– – 0.02% 230
2024
Q1 		$367K Sell
5,300
-400
-7% -$27.5K 0.02% 246
2023
Q4 		$408K Sell
5,700
-300
-5% -$17.3K 0.03% 236
2023
Q3 		$313K Hold
6,000
– – 0.02% 244
2023
Q2 		$380K Sell
6,000
-400
-6% -$24.9K 0.03% 213
2023
Q1 		$347K Hold
6,400
– – 0.03% 214
2022
Q4 		$339K Hold
6,400
– – 0.04% 214
2022
Q3 		$298K Hold
6,400
– – 0.04% 214
2022
Q2 		$365K Sell
6,400
-200
-3% -$11.3K 0.04% 197
2022
Q1 		$404K Sell
6,600
-500
-7% -$26K 0.04% 197
2021
Q4 		$372K Hold
7,100
– – 0.04% 210
2021
Q3 		$265K Sell
7,100
-1,900
-21% -$66.1K 0.04% 223
2021
Q2 		$367K Sell
9,000
-800
-8% -$29.6K 0.06% 182
2021
Q1 		$333K Sell
9,800
-1,200
-11% -$41.6K 0.05% 187
2020
Q4 		$350K Buy
11,000
+200
+2% +$5.26K 0.05% 189
2020
Q3 		$277K Buy
10,800
+200
+2% +$4.56K 0.04% 204
2020
Q2 		$272K Buy
+10,600
New +$215K 0.04% 201

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Van Hulzen Asset Management's ITCI Position: Q2 2025 in Review

Van Hulzen Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 4,600 shares — an estimated $607K sold.

Van Hulzen Asset Management first reported a position in ITCI in Q2 2020 and held it in 20 quarters. The position peaked at $607K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Van Hulzen Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Van Hulzen Asset Management sold 4,600 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $607K.
  • Van Hulzen Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 20 quarters.
  • Van Hulzen Asset Management's Intra-Cellular Therapies Inc. position peaked at $607K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Van Hulzen Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.